The company's Pre-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19 (PREVENT-19) phase III trial showed that NVX-CoV2373 had 90% overall efficacy and 100% protection against moderate and severe COVID-19. The trial included 29,960 participants from 119 sites in the U.S. and Mexico.
Novavax plans to file for regulatory clearance for NVX-CoV2373 in the third quarter of this year. Once the vaccine is cleared for market, Novavax expects to manufacture 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the year.
The company also highlighted positive preclinical data published June 9 on bioRxiv.org regarding its original vaccine and another that it is developing for the COVID-19 Beta variant, B.1.351.
The studies compared the two vaccines for standalone, combination, and heterologous prime booster use, and found that they "demonstrated strong immunogenicity and protection against both the Alpha (B.1.1.7) variant, which was originally identified in the United Kingdom, and the Beta (B.1.351) variant as well as the original SARS-CoV-2 in animal and human studies," the company said.
Copyright © 2021 scienceboard.net